Lupin's Pithampur plant unit completes USFDA inspection

Drug firm Lupin today said a unit of its Pithampur plant in Madhya Pradesh has successfully completed inspection from the US health regulator without any observations.

Unit 1 of the company's Pithampur facility has successfully completed inspection on good manufacturing practice (GMP) as well as PAI (Prior Approval Inspection) by the US Food and Drug Administration (USFDA), Lupin said in a statement.

The USFDA has not made any observations after completion of the inspection, it added.

"The inspection which started on Monday, July 24th concluded today afternoon," Lupin said.

Shares of Lupin today closed at Rs 1,062.85 per scrip on BSE, down 4.34 per cent from its previous close.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)